4.25 tirzepatide Flex-Dose 4 mL Injectable 10 mg/mL Tirzepatide withdrawal leads to 25%

An early study 25 addressed this question by genotyping 9 SNPs associated with serum UA in a series of PD and matched control subjects to obtain a polygenic risk score (PRS) for low UA

Concentration(s) Common formulations:- **PT-141 Injectable:** 10 mg/mL reconstituted solution- **Sermorelin Injectable:** 3 mg/mL, 6 mg/mL, 9 mg/mL- **GHK-Cu Topical:** 0.1% 3%- **NAD+ Injectable:** 100 mg/mL 500 mg/mL- **Oral Troche (PT-141, Sermorelin, NAD+):** 0.5-2 mg per dose Maximum Dosage (Day, Wk) Recommended maximum doses:- **PT-141:** 1.75 mg subcutaneous per dose, max 2 doses per week- **Sermorelin:** 200-500 mcg subcutaneous per dose, daily- **GHK-Cu:** Apply 1-2 times daily- **NAD+:** 50-500 mg subcutaneous per dose, 1-3x per week Contraindications Pregnancy, breastfeeding, active cancer, history of pituitary tumors, cardiovascular disease (for PT-141), history of melanoma (for GHK-Cu), uncontrolled hypertension, or hypersensitivity to any of the compounds

He sees patients at our Fredericksburg Road clinic near the Medical Center and is accepting new patients now

Choosing an experienced pharmacy can help mitigate these risks

Why Proper Reconstitution is Absolutely Non-Negotiable Before we even touch a syringe, we need to establish the stakes